Traws Pharma Inc (TRAW) fair value: what the stock is really worth
As of Oct 16, 2026: fair value (intrinsic value) of Traws Pharma Inc stock $0.62, price $0.37, upside +66.6%, quality 46 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.
How to read this chart
60‑month range $0.3693 – $157.50 · fair‑value band $0.4614 – $0.7688 · the $0.3693 price screens below the $0.6151 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 3, 2026.
Follow Traws Pharma in your weekly email
Every Wednesday you see whether Traws Pharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer.
Show moreShow less
The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza.
It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers.
It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., Knight Therapeutics Inc., Specialised Therapeutics Asia Pte. Ltd., and Temple University.
The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Stock analysis
Traws Pharma Inc (TRAW) currently trades at $0.3693, while our model-based Fair Value estimate is $0.6151, implying the stock looks roughly 40.0% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 7 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: $0.4614 (bear) to $0.7688 (bull), the price of $0.3693 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Traws Pharma Inc reported revenue of $2.8M in FY2025 versus $226K in FY2021, a compound +87.4%/yr. Reported net income was $9.2M in FY2025.
Key figures
Market cap $5.7M Micro · EPS (TTM) $−1.83 · Return on equity −433% · Return on assets (EBIT) −107% · Free cash flow −$20.8M · Net cash $3.8M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 23 out of 100 (medium confidence).
What moves the price
The share trades about 88% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 67%, TRAW screens cheaper than that median.
Fair Value models
Bear$0.4614Fair Value $0.6151Bull$0.7688
Price $0.3693 · Upside +66.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Owner Earnings$4.01$7.97$15.2767
Growth-Adj P/E$19.41$27.72$36.0465
P/E Multiple$9.85$13.13$16.4163
All 7 models by family
DCF Models
Owner Earnings$4.01$7.97$15.2767
Earnings-Based
Graham-Dodd$4.06$28.30$39.7161
Lynch FV$14.62$20.88$27.1559
PEG = 1.0$14.62$20.88$27.1555
Multiples
P/E Multiple$9.85$13.13$16.4163
P/S Multiple$0.4800$0.6400$0.790058
Growth Earnings
Growth-Adj P/E$19.41$27.72$36.0465
The fair value above starts from this blend and is adjusted for dilution from new shares.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.44/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+1,134.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+131.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+64.6%
Start year 2020 (pandemic). Over 10 years: −13.2% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.6%
’13
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−10,819.5% (2020) → −640.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 604 stocks
Beats the industry median on 4/4 measures
Overall it ranks above its industry peers.
Valuation
Quality Score46 · Above median
Fair Value upside+66.6% · Top 25%
Profitability
Return on equity (12 months)Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets86.4% · Top 25%
Operating margin (12 months)0.0% · Above median
Balance sheet
Debt / equityNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/BNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)100· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)0· sector 97
DIVIDEND (yield)0· sector 23
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Traws Pharma Inc (TRAW) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of $0.6151 versus a price of $0.3693, about +67% upside (undervalued).
What is the fair value of TRAW?
Our model-based fair value for Traws Pharma Inc is $0.6151 (as of Oct 3, 2026), built from audited fundamentals. The current price: $0.3693.
What is the quality score of TRAW?
Traws Pharma Inc has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Traws Pharma Inc (TRAW)?
Our model-based price target is the fair value of $0.6151 (as of Oct 3, 2026) from 7 valuation models. Cautious scenario $0.4614, optimistic scenario $0.7688. It is a calculation from audited fundamentals, not an analyst target.
What is the Traws Pharma Inc stock forecast for 2026?
Our models put fair value at $0.6151, about +67% upside versus a price of $0.3693 (undervalued). Cautious scenario $0.4614, optimistic scenario $0.7688. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Traws Pharma Inc (TRAW)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Traws Pharma Inc it is $0.6151 per share (as of Oct 3, 2026), against a price of $0.3693. It is the blended result of 7 valuation models (cash flow, earnings, asset, dividend).
Is Traws Pharma Inc stock overvalued or undervalued in 2026?
As of Oct 3, 2026, TRAW trades below its calculated fair value: price $0.3693, fair value $0.6151, a gap of about +67% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of TRAW?
No. The price is what the market pays today ($0.3693); the fair value is what the company's own numbers justify ($0.6151). For Traws Pharma Inc the two are $0.2458 per share apart. That gap is exactly why we show both numbers side by side.
How much is Traws Pharma Inc worth?
The market values Traws Pharma Inc at about $5.7M (market capitalisation, as of Oct 3, 2026). Per share that is $0.3693; our models calculate a fair value of $0.6151 per share.
What do the bullish and bearish scenarios say about TRAW?
Our models span a range for Traws Pharma Inc: cautious scenario $0.4614, base $0.6151, optimistic $0.7688 per share (as of Oct 3, 2026, price $0.3693). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Traws Pharma Inc (TRAW)?
Balance-sheet figures for Traws Pharma Inc (as of Oct 3, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is TRAW from its 52-week high?
Traws Pharma Inc trades at $0.3693, about 88% below its 52-week high of $3.07 and at the low of $0.3693 (as of Oct 16, 2026). Distance from the high says nothing about value: that is what the fair value of $0.6151 is for.
Which stocks are comparable to Traws Pharma Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Traws Pharma Inc stock attractive at the current price?
The data as of Oct 3, 2026: price $0.3693, calculated fair value $0.6151 (+67%), Quality Score 46/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of TRAW calculated?
We run Traws Pharma Inc through 7 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.6151, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.8 % above its aggregate fair value. Traws Pharma Inc currently trades 40 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Traws Pharma Inc (TRAW)?
The closing price on Oct 16, 2026 was $0.3693. Our model-based fair value is $0.6151, about +67% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Traws Pharma Inc right now?
The price is below even our cautious bear case ($0.4614). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (46/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of Traws Pharma Inc
How large is the market capitalisation of Traws Pharma Inc (TRAW)?
The market capitalisation of Traws Pharma Inc is $5.7M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Traws Pharma Inc (TRAW)?
Earnings per share at Traws Pharma Inc are $−1.83. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Traws Pharma Inc (TRAW)?
The return on equity (ROE) of Traws Pharma Inc is −433% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Traws Pharma Inc (TRAW)?
On an EBIT basis the return on assets of Traws Pharma Inc is −107% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Traws Pharma Inc (TRAW) generate?
The free cash flow of Traws Pharma Inc is −$20.8M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Traws Pharma Inc (TRAW) hold?
Traws Pharma Inc holds more cash than debt, $3.8M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Traws Pharma Inc in the live analysis
One click puts Traws Pharma Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Thin data
Oct 3, 2026